Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and Daratumumab in Autoimmune Encephalitis
NCT06867991Phase 3Recruiting
- Sponsor
- Changzhou First People's Hospital
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ofatumumab and daratumumab in anti-N-methyl D-aspartate receptor encephalitis (3 arms), sponsored by Changzhou First People's Hospital. Primary endpoint: Time to modified Rankin Scale score <= 2 at 16 weeks. Started Nov 2024; status: recruiting.
02
Drugs
ofatumumabdaratumumab
03
Conditions
anti-N-methyl D-aspartate receptor encephalitis
Beyond the preview
Go deeper on NCT06867991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06867991.